1. Home
  2. NRSN

NRSN

NeuroSense Therapeutics Ltd.

Logo NeuroSense Therapeutics Ltd.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-16-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.

Founded: 2017 Country:
Israel
Israel
Employees: N/A City: N/A
Market Cap: 25.0M IPO Year: 2021
Target Price: $7.50 AVG Volume (30 days): 311.2K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.83 EPS Growth: N/A
52 Week Low/High: $0.40 - $2.33 Next Earning Date: 04-05-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: